Antimicrobial resistance turns routine surgery into a rationed service
Prophylaxis reliability falls below the level certain procedures require, and the consequence is administrative: hospital systems formally ration or…
Claude · 2062–2072 · plausible
Prior state
Resistance was rising steadily and was already among the largest attributable causes of death, yet it was experienced as a diffuse background risk. Elective surgery, chemotherapy, intensive care, and neonatal medicine all assumed reliable prophylaxis. New antibiotic development was economically unattractive and sustained mainly by push funding and small subscription pilots.
Material change
Prophylaxis reliability falls below the level certain procedures require, and the consequence is administrative: hospital systems formally ration or relocate elective joint replacement, some cardiac and abdominal procedures, and immunosuppressive regimens according to local resistance profiles and reserve-agent availability. Access to last-line therapy becomes an explicitly allocated entitlement with eligibility criteria, and antibiotic supply is procured through availability payments rather than sales volume, because the only workable business model for a drug that must not be used is to pay for its existence.
Why now
The threshold is crossed when resistance among the specific organisms responsible for surgical-site and device infections passes the point at which procedural infection rates become uninsurable. Given rates observed at the origin and their trajectory, that crossing falls within this window in the highest-burden systems. The institutional response arrives in the same decade because hospital accreditation and malpractice liability, not epidemiology, are what force written rationing rules.
Mechanism and resistance
The mechanism is mundane and organisational: stewardship enforcement, mandatory reporting, procedural relocation to designated low-resistance facilities, and reserve-agent gatekeeping. Resistance comes from surgeons and patients denied procedures, from agricultural interests defending veterinary use, from over-the-counter markets in high-burden countries where restriction is unenforceable and often unjust given the absence of diagnostic access, and from the fiscal difficulty of paying for drugs that generate no revenue.
Consequences
The burden lands on the old, the poor, and the rural, who lose access to procedures that remain available at designated centres. Medical travel reverses direction for some procedures, flowing toward jurisdictions with better infection control rather than lower prices. Phage, monoclonal, and microbiome-based approaches supplement but do not replace small-molecule antibiotics, and the decade ends with the problem contained rather than solved.
End state
By 2072 elective surgical access is stratified by facility resistance profile in several large health systems, reserve antibiotics are allocated under formal criteria, and antibiotic supply in high-income systems runs mainly through availability payments.
Observable test
Published hospital or national protocols condition elective procedure eligibility on resistance profiles and reserve-agent availability; procedure volumes shift measurably toward designated facilities; subscription or availability-payment contracts become the dominant procurement route for reserve agents in several large systems.
Disconfirming sign
New antibiotic classes or non-antibiotic prophylaxis restore reliable surgical prophylaxis, and elective volumes are unrationed, with resistance handled purely as a stewardship matter.
Themes
Related model consensus
Antimicrobial resistance reorganizes and rations routine medicine